[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth
View original at finance.yahoo.com[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth F. Hoffmann-La Roche Ltd Group sales grew by 7%1 at constant exchange rates (CER; 2% in CHF), driven by strong demand for medicines and diagnostic solutions…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Roche expects mid single-digit sales growth (CER) and high single-digit core EPS growth (CER) in 2026, with further dividend increase expected in CHF.
80% confidenceFenebrutinib is the first and only BTK inhibitor with positive results in both relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).
80% confidenceGazyva/Gazyvaro would be the first anti-CD20 therapy for systemic lupus erythematosus targeting B cells.
80% confidenceUp to 135,000 people are affected by lupus nephritis in the European Union.
80% confidenceLubomira Rochet brings a broad leadership track record and deep experience in business transformations through digital and technology.
80% confidence2025 was a strong year for Roche, reflecting continued focus on operational and R&D excellence with ten potential new medicines advanced into final-stage development and 12 late-stage clinical studies delivered positive results. Company is well positioned for growth.
80% confidenceUp to 3.4 million people worldwide are affected by systemic lupus erythematosus.
80% confidenceGiredestrant represents the first significant endocrine therapy advance in over 20 years for the adjuvant setting in early breast cancer.
80% confidenceUp to 70% of all breast cancer cases are ER-positive, and up to 1/3 experience recurrence on or after adjuvant endocrine therapy.
80% confidencecobas liat Bordetella panel is the first point-of-care test for Bordetella infections including pertussis.
80% confidencecobas Mass Spec solution offers the broadest menu in the industry with 39 in vitro diagnostic tests.
80% confidence